


### Claims

1. A dicarboxylic acid salt of sibutramine, represented by the following Chemical Formula 1:

Chemical Formula 1



5

wherein, n is an integral number of 0 or 1.

2. The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine oxalate having an X-ray diffraction pattern in which peaks appear at 2θ values of 5.46, 10.92, 12.16, 12.74, 14.92, 15.44, 15.78, 17.4, 19.24, 21.3, 22.0, 22.92, 24.54, 25.3, 25.8, 27.52, 28.74, 28.92, 30.12, 33.26, 35.04, and 39.76.

10

3. The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine malonate having an X-ray diffraction pattern in which peaks appear at 2θ values of 7.7, 10.74, 11.08, 11.56, 15.42, 15.78, 17.24, 17.84, 18.1, 19.02, 19.68, 21.54, 21.9, 22.24, 22.88, 23.26, 23.64, 24.44, 24.72, 26.0, 27.6, 28.4, 28.62, and 29.3.

15

4. A method of preparing the dicarboxylic acid salt  
of sibutramine represented by Chemical Formula 1 according  
to claim 1, comprising reacting sibutramine with a  
dicarboxylic acid selected from among oxalic acid and  
5 malonic acid in an inert solvent.

5. A pharmaceutical composition for treating or  
preventing obesity and related disorders, depression,  
Parkinson's disease, insulin-independent diabetes mellitus  
or epilepsy, comprising the dicarboxylic acid salt of  
10 sibutramine represented by Chemical Formula 1 according to  
claim 1 as an effective ingredient.

6. The pharmaceutical composition as set forth in  
claim 5, which is formulated into tablets or capsules.

7. A method of treating or preventing obesity and  
15 related disorders, depression, Parkinson's disease,  
insulin-independent diabetes mellitus or epilepsy,  
comprising administering the pharmaceutical composition of  
claim 5.